Drug Search Results
More Filters [+]

Mivacurium chloride

Alternative Names: mivacurium chloride, mivacurium, mivacron
Latest Update: 2024-11-28
Latest Update Note: Clinical Trial Update

Product Description

Mivacurium chloride (Mivacron) is a new benzylisoquinolinium choline-like diester neuromuscular blocking drug with an onset of action at equipotent doses that is comparable to atracurium and vecuronium but slower than succinylcholine.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/1373287/)

Mechanisms of Action: nAChR Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Inhalant

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Australia | Austria | Belgium | Brazil | Canada | Chile | Czech | Denmark | Finland | France | Germany | Hong Kong | Hungary | Ireland | Italy | Lithuania | Luxembourg | Malaysia | Malta | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Romania | Singapore | Slovenia | South Africa | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Kingdom | Uruguay

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Mivacurium chloride

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events